Latest Breaking News On - Board mark velleca - Page 1 : vimarsana.com

Presented BDTX-1535 Phase 1 dose escalation data showing durable anti-tumor activity and favorable safety profile in NSCLC patients across heterogeneous EGFR mutations at the October 2023.

United statesUnited kingdomBlack diamondMario corsoMark vellecaJulie seidelDrug administrationExchange commissionIvy brain tumor centerDevelopment expensesCompany masterkeyInternational conference on molecularDiamond therapeutics incMolecular targetsDiamond therapeuticsChief executive officer